Our mission is to harness the power of the immune system to bring affordable, curative therapies to cancer patients
Today, we can create drugs that empower the immune system to do its job – cure disease.
How does botensilimab work?
By modifying the Fc “tail” of the antibody, our scientists discovered that its efficacy and tolerability can be significantly enhanced.
Our diverse portfolio of immunotherapies, vertically integrated capabilities from discovery through manufacturing, and partnerships with industry leaders uniquely position us to adopt a comprehensive approach to discover and develop cancer therapies.
Agenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics), adjuvants and vaccines (through subsidiary SaponiQx).
We have brought together top talent and expertise to advance our mission, building a team of over 400 employees across our offices in the US and Europe.